Patent Ruling May Mean Trouble for Big Pharma
When someone seeks a patent, they must convince authorities that their inventions aren't completely apparent and are therefore worthy of protection. "Now, there is more flexibility for patent examiners in establishing that an invention is obvious," Bagley says. "And that creates more challenges for patent applicants."
Bagley says the previous strict standards had been guided by the Court of Appeals for the Federal Circuit, which hears all appeals of patent-infringement cases. Because the Supreme Court rarely hears patent cases, the appeals court "was perceived to be a mini-Supreme Court" for patent law, she says.
In recent years, however, the high court has taken renewed interest in patent law. Now, inventors "will have to be more diligent" in making claims and providing data, Bagley says.
Room for Interpretation
Bruce Downey, chairman and CEO of Barr Laboratories, said the "obviousness" standard will play a key role in the Razadyne case, as well as in upcoming legal fights over J&J's oral contraceptive TriCyclen-Lo and Bayer's (BAY) contraceptive Yasmin."I think the Supreme Court case has a very direct impact," Downey said in a meeting with analysts earlier this month. "It's a very significant development." On May 11, Barr, who has contended that the J&J patent is invalid and whose dispute with the Razadyne maker has been in court since June 2005, received tentative approval from the Food and Drug Administration to market three dosage strengths of drug.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV